0001062993-21-007502.txt : 20210813 0001062993-21-007502.hdr.sgml : 20210813 20210813183530 ACCESSION NUMBER: 0001062993-21-007502 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210812 FILED AS OF DATE: 20210813 DATE AS OF CHANGE: 20210813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CRANDELL KEITH CENTRAL INDEX KEY: 0001219039 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38720 FILM NUMBER: 211173736 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Twist Bioscience Corp CENTRAL INDEX KEY: 0001581280 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 462058888 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 800-719-0671 MAIL ADDRESS: STREET 1: 681 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2021-08-12 0001581280 Twist Bioscience Corp TWST 0001219039 CRANDELL KEITH C/O ARCH VENTURE PARTNERS IX, LLC 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 1 0 0 0 Common Stock 2021-08-12 4 S 0 1412 106.93 D 486 D Common Stock 2021-08-12 4 S 0 41033 106.9765 D 78602 I By Keith L. Crandell Trust Common Stock 2021-08-12 4 S 0 2555 107.5638 D 76047 I By Keith L. Crandell Trust Common Stock 2021-02-11 4 J 0 286480 0 D 440354 I By Arch Venture Fund VII, L.P. Common Stock 2021-02-11 4 J 0 14560 0 A 97252 I By Keith L. Crandell Trust Common Stock 2021-02-11 4 J 0 113520 0 D 174584 I By ARCH Venture Fund VIII Overage, L.P. Common Stock 2021-02-11 4 J 0 1 0 A 97253 I By Keith L. Crandell Trust Common Stock 2021-05-13 4 J 0 214828 0 D 225526 I By ARCH Venture Fund VII, L.P. Common Stock 2021-05-13 4 J 0 10918 0 A 108171 I By Keith L. Crandell Trust Common Stock 2021-05-13 4 J 0 85172 0 D 89412 I By ARCH Venture Fund VIII Overage, L.P. Common Stock 2021-05-13 4 J 0 1 0 A 108172 I By Keith L. Crandell Trust Common Stock 2021-05-19 4 J 0 225526 0 D 0 I By ARCH Venture Fund VII, L.P. Common Stock 2021-05-19 4 J 0 11462 0 A 119634 I By Keith L. Crandell Trust Common Stock 2021-05-19 4 J 0 89412 0 D 0 I By ARCH Venture Fund VIII Overage, L.P. Common Stock 2021-05-19 4 J 0 1 0 A 119635 I By Keith L. Crandell Trust Pro-rata distribution of Common Stock held by a limited partnership to its partners for no consideration. The shares were directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The shares were directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Keith Crandell is a managing director of ARCH VII LLC and ARCH VIII LLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Change in form of ownership of shares previously reported as beneficially owned by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.39 to $107.37. The reporting person undertakes to provide to TWST, any security holder of TWST, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.405 to $107.70. /s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell 2021-08-13